"Luteinizing Hormone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Luteinizing hormone regulates steroid production by the interstitial cells of the TESTIS and the OVARY. The preovulatory LUTEINIZING HORMONE surge in females induces OVULATION, and subsequent LUTEINIZATION of the follicle. LUTEINIZING HORMONE consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH and FSH), but the beta subunit is unique and confers its biological specificity.
| Descriptor ID |
D007986
|
| MeSH Number(s) |
D06.472.699.322.576.463 D06.472.699.631.525.343.463 D12.644.548.691.525.343.463
|
| Concept/Terms |
Luteinizing Hormone- Luteinizing Hormone
- Hormone, Luteinizing
- Lutropin
- LH (Luteinizing Hormone)
- ICSH (Interstitial Cell Stimulating Hormone)
- Interstitial Cell-Stimulating Hormone
- Hormone, Interstitial Cell-Stimulating
- Interstitial Cell Stimulating Hormone
|
Below are MeSH descriptors whose meaning is more general than "Luteinizing Hormone".
Below are MeSH descriptors whose meaning is more specific than "Luteinizing Hormone".
This graph shows the total number of publications written about "Luteinizing Hormone" by people in this website by year, and whether "Luteinizing Hormone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 3 | 3 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 2 | 2 | 4 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 2 | 0 | 2 |
| 2009 | 0 | 1 | 1 |
| 2012 | 1 | 1 | 2 |
| 2014 | 1 | 1 | 2 |
| 2016 | 1 | 1 | 2 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2022 | 0 | 2 | 2 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Luteinizing Hormone" by people in Profiles.
-
Klein K, Klein KO, Miller BS, Mauras N. Unstimulated Luteinizing Hormone for Assessment of Suppression during Treatment of Central Precocious Puberty with 6-Month Subcutaneous Leuprolide Acetate: Correlations with Clinical Response. Horm Res Paediatr. 2025; 98(5):514-523.
-
Pirtea P, de Ziegler D, Marin D, Sun L, Tao X, Ayoubi JM, Franasiak J, Scott RT. Gonadotropin receptor polymorphisms (FSHR N680S and LHCGR N312S) are not predictive of clinical outcome and live birth in assisted reproductive technology. Fertil Steril. 2022 09; 118(3):494-503.
-
Butt MS, Saleem J, Aiman S, Zakar R, Sadique I, Fischer F. Serum anti-M?llerian hormone as a predictor of polycystic ovarian syndrome among women of reproductive age. BMC Womens Health. 2022 05 28; 22(1):199.
-
Carpinello O, DeCherney A. The Lion King of ovulation induction. Fertil Steril. 2020 11; 114(5):983.
-
Shore ND, Guerrero S, Sanahuja RM, Gamb?s G, Parente A. A New Sustained-release, 3-Month Leuprolide Acetate?Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer. Clin Ther. 2019 03; 41(3):412-425.
-
Morin SJ, Tao X, Marin D, Zhan Y, Landis J, Bedard J, Scott RT, Seli E. DNA methylation-based age prediction and telomere length in white blood cells and cumulus cells of infertile women with normal or poor response to ovarian stimulation. Aging (Albany NY). 2018 12 08; 10(12):3761-3773.
-
Klein K, Yang J, Aisenberg J, Wright N, Kaplowitz P, Lahlou N, Linares J, Lundstr?m E, Purcea D, Cassorla F. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty. J Pediatr Endocrinol Metab. 2016 Nov 01; 29(11):1241-1248.
-
Chang FE, Beall SA, Cox JM, Richter KS, DeCherney AH, Levy MJ. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response. Fertil Steril. 2016 Oct; 106(5):1093-1100.e3.
-
Werner MD, Forman EJ, Hong KH, Franasiak JM, Molinaro TA, Scott RT. Defining the "sweet spot" for administered luteinizing hormone-to-follicle-stimulating hormone gonadotropin ratios during ovarian stimulation to protect against a clinically significant late follicular increase in progesterone: an analysis of 10,280 first in?vitro fertilization cycles. Fertil Steril. 2014 Nov; 102(5):1312-7.
-
Lee PA, Klein K, Mauras N, Lev-Vaisler T, Bacher P. 36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty. J Clin Endocrinol Metab. 2014 Sep; 99(9):3153-9.